Jaswinder Samra

Prof. Dr. Jaswinder Samra

Northern Clinical School, The University of Sydney, Sydney, Australia
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TCTerence C. Chua
Terence C. Chua
TYTimothy X. Yang
Timothy X. Yang
AGAnthony J. Gill
Anthony J. Gill
JSJaswinder Samra
Jaswinder Samra

Verified
Journal Article
Open access
PDF file
SMSarah Maloney
Sarah Maloney
NPNick Pavlakis
Nick Pavlakis
MIMalinda Itchins
Malinda Itchins
JAJennifer Arena
Jennifer Arena
AMAnubhav Mittal
Anubhav Mittal
SCStephen Clark
Stephen Clark
Pancreatic cancer has poor survival despite modern-day advances in its management. At present, there are no available biomarkers that can predict chemotherapy response or help inform prognosis. In more recent years, there has been increased interest in potential inflammatory biomarkers, with studies revealing a worse prognosis of patients with a higher neutrophil-to-lymphocyte ratio in a range of tumour types. Our aim was to assess the role of three inflammatory biomarkers in peripheral blood in predicting chemotherapy response in patients with earlier disease treated with neoadjuvant chemotherapy and as a prognostic marker in all patients that underwent surgery for pancreatic cancer. Using retrospective records, we discovered that patients with a higher neutrophil-to-lymphocyte ratio (>5) at the time of diagnosis had worse median overall survival than those with ratios ≤5 at 13 and 32.4 months (p = 0.001, HR 2.43), respectively. We were able to appreciate a correlation between a higher platelet-to-lymphocyte ratio and increased residual tumour in the histopathological specimen in patients receiving neoadjuvant chemotherapy; however, the association was weak (p = 0.03, coefficient 0.21). Due to the dynamic relationship between the immune system and pancreatic cancer, it is unsurprising that immune markers may be useful as potential biomarkers; however, larger prospective studies are needed to validate these findings.

24 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Josef GillsonJosef Gillson
Josef Gillson
YRYogambha Ramaswamy
Yogambha Ramaswamy
GSGurvinder Singh
Gurvinder Singh
AGAlemayehu Gorfe
Alemayehu Gorfe
NPNick Pavlakis
Nick Pavlakis
Sumit SahniSumit Sahni
Sumit Sahni
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors in the world. Currently, there are no approved targeted therapies for PDAC. Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are known to be a major driver of PDAC progression, but it was considered an undruggable target until recently. Moreover, PDAC also suffers from drug delivery issues due to the highly fibrotic tumor microenvironment. In this perspective, we provide an overview of recent developments in targeting mutant KRAS and strategies to overcome drug delivery issues (e.g., nanoparticle delivery). Overall, we propose that the antitumor effects from novel KRAS inhibitors along with strategies to overcome drug delivery issues could be a new therapeutic way forward in PDAC.

20 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Josef GillsonJosef Gillson
Josef Gillson
YEYomna S. Abd El-Aziz
Yomna S. Abd El-Aziz
LLLionel Y. W. Leck
Lionel Y. W. Leck
Patric J. JanssonPatric J. Jansson
Patric J. Jansson
NPNick Pavlakis
Nick Pavlakis
Sumit SahniSumit Sahni
Sumit Sahni
Pancreatic cancer is known to have the lowest survival outcomes among all major cancers, and unfortunately, this has only been marginally improved over last four decades. The innate characteristics of pancreatic cancer include an aggressive and fast-growing nature from powerful driver mutations, a highly defensive tumor microenvironment and the upregulation of advantageous survival pathways such as autophagy. Autophagy involves targeted degradation of proteins and organelles to provide a secondary source of cellular supplies to maintain cell growth. Elevated autophagic activity in pancreatic cancer is recognized as a major survival pathway as it provides a plethora of support for tumors by supplying vital resources, maintaining tumour survival under the stressful microenvironment and promoting other pathways involved in tumour progression and metastasis. The combination of these features is unique to pancreatic cancer and present significant resistance to chemotherapeutic strategies, thus, indicating a need for further investigation into therapies targeting this crucial pathway. This review will outline the autophagy pathway and its regulation, in addition to the genetic landscape and tumor microenvironment that contribute to pancreatic cancer severity. Moreover, this review will also discuss the mechanisms of novel therapeutic strategies that inhibit autophagy and how they could be used to suppress tumor progression.

1 April 2015 in Surgery
Verified
Journal Article
Closed access
AMAnubhav Mittal
Anubhav Mittal
PRPhilip R. de Reuver
Philip R. de Reuver
SSSatya Shanbhag
Satya Shanbhag
RSRalph F. Staerkle
Ralph F. Staerkle
MNMichael Neale
Michael Neale
JSJaswinder Samra
Jaswinder Samra

14 February 2019 in Endocrine Pathology
Verified
Journal Article
Closed access
PDF file
PGPreetjote Gill
Preetjote Gill
EKEdward Kim
Edward Kim
TCTerence C. Chua
Terence C. Chua
RCRoderick J. Clifton-Bligh
Roderick J. Clifton-Bligh
CNChristopher B. Nahm
Christopher B. Nahm
JSJaswinder Samra
Jaswinder Samra